Jika mau, Anda dapat mengirim email kepada kami dengan deskripsi mendetail tentang masalah Anda atau menelusuri bagian FAQ yang komprehensif kami mendapatkan jawaban instan.Unfit sufferers even have the alternative of venetoclax as well as obinutuzumab (VO) as frontline therapy. This is based over a section III trial that as opposed VO with ClbO in